ArticleNucleic acids research2026
RaptScore: a large language model-based algorithm for versatile aptamer evaluation.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- SELEX-Based Aptamer Technologies for Toxin Analysis: Screening, Optimization, and Computational Assisted Design.Toxins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
RNA aptamers are a high-potency tool in the life sciences, offering promising applications in drug discovery and beyond. They are typically obtained through systematic evolution of ligands by exponential enrichment (SELEX), which imposes constraints on sequence length and diversity. Several metrics, such as frequency and enrichment, have been developed to identify high-activity aptamers from SELEX. However, existing evaluation metrics are limited to sequences that appear within SELEX and cannot assess sequences of varying lengths, limiting their utility in optimizing aptamer design. To overcome these limitations, we developed RaptScore, a novel binding activity evaluation metric leveraging large language models. RaptScore enables the assessment of arbitrary sequences, including those absent from SELEX, and accommodates variations in sequence length. RaptScore exhibited a strong correlation with binding activity, allowing the identification of shorter aptamers with enhanced binding properties. By integrating RaptScore with in silico maturation, we achieved a 10-nucleotide truncation while maintaining binding efficiency. Furthermore, we demonstrated improved aptamer discovery efficiency by combining RaptScore with RaptGen, a variational autoencoder-based aptamer discovery tool. By enabling efficient sequence evaluation and optimization, RaptScore provides a powerful tool for aptamer research, facilitating the discovery of high-activity candidates while reducing experimental effort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.